跳至主要内容
临床试验/NCT06305390
NCT06305390招募中不适用

Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.

IRCCS San Raffaele1 个研究点 分布在 1 个国家目标入组 167 人开始时间: 2023年12月4日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
167
试验地点
1
主要终点
To assess the accuracy and the predictive value of fully hybrid 18F-PSMA PET/MRI for the diagnosis of clinically significant prostate cancer (csPCa)

研究概览

简要总结

This project aims to evaluate the role of fully hybrid PET/MRI with 18FPSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa).

Our main hypothesis is that adding 18F-PSMA PET to mpMRI prior to biopsy, will reduce the number of false negative findings, while at the same time, allowing also to reduce the number of unnecessary prostate biopsies in patients with low-risk, clinically indolent PCa.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men at least 18 years of age referred with clinical suspicion of prostate cancer candidate for prostate biopsy
  • Feasibility to undergo all procedures listed in protocol
  • Ability to provide written informed consent

排除标准

  • Prior diagnosis of prostate cancer
  • Contraindication to MRI (e.g. claustrophobia, pacemaker, estimated GFR lower or equal to 50mls/min)
  • Contraindication to prostate biopsy

结局指标

主要结局

To assess the accuracy and the predictive value of fully hybrid 18F-PSMA PET/MRI for the diagnosis of clinically significant prostate cancer (csPCa)

时间窗: PET/MRI: day 0 prostate biopsy: day 0-90 days

Diagnostic accuracies of 18F-PSMA PET and mpMRI will be calculated by means of sensitivity: true positive/(true positive + false negative) and specificity: true negative/(false positive + true negative) using the prostate biopsy result as reference standard.

次要结局

  • To compare the proportion of csPCa missed by 18F-PSMA PET scan or mpMRI alone To report the reduction in the detection of clinically insignificant PCa when combining mpMRI and 18F-PSMA PET(PET/MRI: day 0 prostate biopsy: day 0-90 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chiti Arturo

PI

IRCCS San Raffaele

研究点 (1)

Loading locations...

相似试验

Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach... | 临床试验